Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
LENZ Therapeutics is a clinical-stage ophthalmic pharmaceutical company developing LNZ100 (aceclidine) and LNZ101, presbyopia-correcting eye drops targeting the $30+ billion global presbyopia market. The company is pre-revenue with a single lead asset in late-stage development, positioning it as a pure-play binary bet on FDA approval and commercial launch timing. With $155M+ cash runway and no debt, LENZ has sufficient capital to reach pivotal Phase 3 readouts expected in 2026-2027.
LENZ is developing once-daily presbyopia eye drops as an alternative to reading glasses for the 128 million Americans aged 45+ with near-vision impairment. The business model depends on achieving FDA approval through Phase 3 trials (CLARITY program), then commercializing through specialty ophthalmology sales channels or strategic partnerships. Pricing power derives from addressing a massive underserved market with limited pharmaceutical alternatives - current options include Vuity (Allergan/AbbVie) and surgical procedures. Success requires demonstrating superior efficacy, duration, or safety profile versus Vuity's pilocarpine formulation. Revenue generation is 2-3 years away, contingent on positive Phase 3 data and regulatory approval.
Phase 3 CLARITY trial enrollment milestones and topline data readouts (primary efficacy endpoints on visual acuity improvement)
FDA regulatory interactions, breakthrough therapy designation status, and NDA submission timing
Competitive developments from AbbVie's Vuity market penetration, pricing, and real-world adoption data
Cash runway updates and potential dilutive financing events given negative $100M annual cash burn
Partnership or licensing announcements for ex-US commercialization rights
Binary FDA approval risk - entire valuation depends on Phase 3 trial success and regulatory clearance for single asset with no diversified pipeline
Competitive obsolescence risk from next-generation presbyopia treatments including gene therapies, extended-release implants, or superior pharmacological formulations
Reimbursement uncertainty as presbyopia drops may face coverage challenges from Medicare/commercial payers who view reading glasses as adequate low-cost alternative
AbbVie's Vuity (pilocarpine 1.25%) has first-mover advantage with 2021 approval and established ophthalmology sales infrastructure - LENZ must demonstrate differentiation
Large-cap pharma competitors (Novartis, Roche ophthalmology divisions) could enter market with superior resources for clinical development and commercialization
Generic reading glasses and over-the-counter solutions provide low-cost alternatives that limit addressable market penetration
Equity dilution risk from future financing needs - current $100M annual burn rate requires capital raise within 18-24 months if no partnership materializes
Clinical trial cost overruns or timeline delays could accelerate cash consumption and force dilutive financing at depressed valuations (stock down 66% in six months)
low - Clinical trial timelines and FDA approval processes are largely insulated from GDP fluctuations. However, post-approval commercial success would show moderate sensitivity as presbyopia treatment is elective healthcare spending (patients can defer or use reading glasses). Recession could reduce patient willingness to pay out-of-pocket for non-reimbursed eye drops.
High interest rates negatively impact LENZ through multiple channels: (1) Higher discount rates compress NPV of future cash flows, particularly punitive for pre-revenue biotechs with 3-5 year monetization timelines; (2) Reduced risk appetite among biotech investors shifts capital away from clinical-stage names; (3) Higher yields make cash-burning growth stocks less attractive versus fixed income alternatives. Rising rates have contributed to the 66% six-month decline as biotech valuations contracted sector-wide in 2025-2026.
Minimal direct credit exposure given zero debt and strong 12.69x current ratio. However, tightening credit conditions indirectly impact through reduced venture capital and public market financing availability for follow-on offerings. LENZ will likely require additional capital raises before achieving profitability, making equity market conditions critical.
growth - Attracts speculative biotech investors seeking asymmetric risk/reward from binary FDA approval catalysts. Typical holders include healthcare-focused hedge funds, biotech venture funds, and retail investors with high risk tolerance. Not suitable for value or income investors given pre-revenue status and negative cash flow. The 55% three-month decline reflects momentum capitulation as clinical timelines extend.
high - Clinical-stage biotech with single asset exhibits extreme volatility around trial readouts and regulatory milestones. Recent 48.6% one-year decline and 66% six-month drawdown demonstrate sensitivity to sector rotation and risk-off sentiment. Expect 20-50% single-day moves on Phase 3 data releases. Beta likely exceeds 2.0x relative to broader biotech indices.
